Inflammation and Immunity
Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Thierry Sornasse, Ph.D., AbbVie (Co-Chair)

David Fox, M.D., University of Michigan (Co-Chair)

Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics

Tara Altepeter, M.D., FDA/CDER

Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S

Kristina Beeler, Ph.D., Ms.C., Biognosys

Robert Benschop, Ph.D., Eli Lilly

Maria Bettinotti, Ph.D., Johns Hopkins University

Jonathan Blackburn, Ph.D., Sengenics

Jonathon Brzezinski, Ph.D., Clarivate

Preethi Chander, Ph.D., NIDCR/NIH

Kelly Chun, Ph.D., LabCorp

Janet Church, Sjögren’s Foundation

Albert Crescenzo, Ph.D., Clarivate

Carolyn Cuff, Ph.D., Janssen

Thomas Daly, M.D., Eli Lilly

Sahar Dawisha, M.D., FDA/CDRH

Natasha de Peyrecave, D. Phil., UCB

Betty Diamond, Ph.D., Feinstein Institute

Renee Donahue, Ph.D., NIH/NCI

Ed Driggers, Ph.D., General Metabolics

Kellie Feck, Olink

Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation

Julie Fiore, M.D., Ph.D., Merck

Dan Fitzpatrick, Ph.D., Amgen

Thomas Fuerst, Ph.D., Clario

Rebecca Fuldner, Ph.D., NIH/NIA

Alessandra Geremia, Ph.D., GSK

Mireia Guerau, PharmD, Ph.D., NIH/NIAID

Arcan Guven, Ph.D., Biogen

Kathy Hammitt, M.A., Sjogren’s Foundation

Stephanie Hennek, Ph.D., PathAI

Andrea Hooper, Ph.D, Regeneron

Ewan Hunter, Oxford Biodynamics

Andres Hurtado-Lorenzo, Crohn’s & Colitis Foundation

Angelika Jahreis, Novartis

Christina Jayson, Path AI

Chao Jiang, Ph.D., NIAID/NIH

Daniel Johnston, Ph.D., NIH/NICHD

Kathy Jung, Ph.D., NIH/NIAAA

Jason Kim, Ph.D., Arthritis Foundation

Ernst Kriehuber, M.D., UCB

Stephen Laroux, Ph.D., AbbVie

Steven Leonard, Johnson & Johnson

David Martin, M.D., Pfizer

Russell McBride, Ph.D., MPH, Icahn School of Medicine at Mount Sinai

Alan Moss, M.D,. Crohn’s & Colitis Foundation of America

Sumanta Mukherjee, Ph.D., GlaxoSmithKline

Nikolay Nikolov, M.D., FDA/CDER

Mariaelena Occhipinti, M.D., Ph.D., Radiomics

Heiyoung Park, Ph.D., NIAMS/NIH

Jane Parnes, M.D., Amgen

Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis

Josh Porter, Olink Proteomics

Rubio Punzalan, Ph.D., LabCorp

John Reveille, M.D., University of Texas Health Science Center (Houston)

Lisa Rider, M.D., NIH/NIEHS

Jane Salmon, M.D., Hospital for Special Surgery

Johannes Scheid, M.D., Ph.D., Merck

Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research

Susana A. Serrate-Sztein, M.D., NIH/NIAMS

Vicki Shanmugam, MBBS, MRCP, FACR, CCD, NIH / OADR

Diane Shevell, Ph.D., Novartis

Glennda Smithson, Ph.D., Takeda

Lisa Spain, Ph.D., NIH/NIDDK

Emily Boyd Stormoen, Arthritis National Research Foundation

Fred Sundberg, Sengenics

Mark Tengowski, Ph.D., Clario

Paresh Thakker, Ph.D., Takeda

Mulualem Tilahun, DVM, Ph.D., NIH/NIA/DAB

Candance Tingen, Ph.D., NIH/NICHD

Marco Tognetti, Biognosys

Sudha Visvanathan, Ph.D., Boehringer Ingelheim

Wim Vos, Ph.D., Radiomics

Tony Wagner, Ph.D., Jazz Pharmaceuticals

Joe Wang, Ph.D., NIH/NIAAA

Ilan Wapinski, Ph.D., Sanofi

Michael Weisman, M.D., Stanford University

Mary Wheatley, CAE, National Scleroderma Foundation

Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine

Joel Wommack, Ph.D., SomaLogic

Jennifer Yoon, Somalogic